✦ LIBER ✦

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

✍ Scribed by Jain, N.; Curran, E.; Iyengar, N. M.; Diaz-Flores, E.; Kunnavakkam, R.; Popplewell, L.; Kirschbaum, M. H.; Karrison, T.; Erba, H. P.; Green, M.; Poire, X.; Koval, G.; Shannon, K.; Reddy, P. L.; Joseph, L.; Atallah, E. L.; Dy, P.; Thomas, S. P.; Smith, S. E.; Doyle, L. A.; Stadler, W. M.; Larson, R. A.; Stock, W.; Odenike, O.

Book ID: 126626059
Publisher: American Association for Cancer Research
Year: 2013
Tongue: English
Weight: 462 KB
Volume: 20
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.CCR-13-1311

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cediranib in patients with malignant mes

Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

✍ Campbell, Nicholas P.; Kunnavakkam, Rangesh; Leighl, Natasha; Vincent, Mark D.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 381 KB

A University of Chicago Consortium Phase

A University of Chicago Consortium Phase II Trial of SB-715992 in Advanced Renal Cell Cancer

✍ Richard T. Lee; Kathleen E. Beekman; Maha Hussain; Nancy B. Davis; Joseph I. Cla 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 109 KB

Dasatinib in previously treated metastat

Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium

✍ Manish R. Sharma, Kristen Wroblewski, Blase N. Polite, James A. Knost, James A. 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 162 KB

DOC-MEK: a double-blind randomized phase

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma

✍ Gupta, A.; Love, S.; Schuh, A.; Shanyinde, M.; Larkin, J. M.; Plummer, R.; Natha 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 202 KB

Phase II trial of cis-dichlorodiamminepl

Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B

✍ F. Cavalli; Dr. W. F. Jungi; N. I. Nissen; T. F. Pajak; M. Coleman; J. F. Hollan 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 3 views

In a cooperative study of the Cancer and Acute Leukemia Group B, 27 evaluable patients with advanced malignant lymphomas were treated with 70 mg/m2 of cisdichlorodiammineplatinum(l1) (cis-platinum) once every three weeks. All patients had received extensive prior therapy. Partial remission was obtai

A phase II study of sorafenib in advance

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia

✍ Halla S. Nimeiri; Amit M. Oza; Robert J. Morgan; Dezheng Huo; Laurie Elit; James 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 230 KB